Product
Venetoclax/Acalabrutinib
1 clinical trial
1 indication
Clinical trial
A Prospective, Multicenter, Phase-II Trial of Venetoclax Plus Acalabrutinib in Patients Who Have Relapsed After First Line Venetoclax + Anti-CD20 mAb Treatment for Chronic Lymphocytic Leukemia (CLL or SLL)Status: Recruiting, Estimated PCD: 2028-12-01